Internal Medicine
Rapid Remission and Low Disease Activity: Real-World Evidence for Anifrolumab in Systemic Lupus Erythematosus
Interim data from the multicentre REVEAL study demonstrate that anifrolumab facilitates rapid disease control in real-world SLE patients, with 66% achieving low disease activity within six months, particularly in those with mucocutaneous an
